{"transactions":[{"id":763905,"issuer":{"id":4384,"kind":"organization","name":"Nuvation Bio Inc."},"owners":[{"id":44249,"kind":"person","name":"Cui Xiangmin","position":1,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-27T00:01:53.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":123397,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 21, 2026); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date."}],"balance_after":123397,"derivative":{"exercise_price":4.79,"expiration_date":"2036-05-20","underlying":"Class A Common Stock","underlying_shares":123397},"source":{"system":"sec-edgar","filing":"0001487815-26-000007","document":"form4-05272026_120549.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1811063/000148781526000007/form4-05272026_120549.xml","form_type":"4"}},{"id":763903,"issuer":{"id":4384,"kind":"organization","name":"Nuvation Bio Inc."},"owners":[{"id":44249,"kind":"person","name":"Cui Xiangmin","position":1,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-27T00:01:13.000Z","date":"2026-02-27","kind":"grant","planned":false,"acquired":true,"shares":76923,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On March 3, 2026, the reporting person filed a Form 4 which, due to an administrative error, incorrectly reported that the reporting person was awarded 74,813 options to purchase Class A Common Stock on February 27, 2026. In fact, the reporting person was awarded 76,923 options to purchase Class A Common Stock on such date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Option vests as to 1/24 of the shares on the one month anniversary of 1/1/2026, monthly thereafter over the following 23 months, subject to Reporting Person's continuous service on each such vesting date"}],"balance_after":76923,"derivative":{"exercise_price":5.91,"expiration_date":"2036-02-26","underlying":"Class A Common Stock","underlying_shares":76923},"source":{"system":"sec-edgar","filing":"0001487815-26-000006","document":"form4a-05272026_120510.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1811063/000148781526000006/form4a-05272026_120510.xml","form_type":"4/A","original_submission_date":"2026-03-03"}},{"id":867963,"issuer":{"id":4384,"kind":"organization","name":"Nuvation Bio Inc."},"owners":[{"id":44249,"kind":"person","name":"Cui Xiangmin","position":1,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-04T00:58:08.000Z","date":"2026-02-27","kind":"grant","planned":false,"acquired":true,"shares":74813,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests as to 1/24 of the shares on the one month anniversary of 1/1/2026, monthly thereafter over the following 23 months, subject to Reporting Person's continuous service on each such vesting date."}],"balance_after":74813,"derivative":{"exercise_price":5.91,"expiration_date":"2036-02-26","underlying":"Class A Common Stock","underlying_shares":74813},"source":{"system":"sec-edgar","filing":"0001487815-26-000003","document":"form4-03042026_120305.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1811063/000148781526000003/form4-03042026_120305.xml","form_type":"4"}},{"id":1015827,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74132,"kind":"organization","name":"Decheng Capital Management II (Cayman), LLC","position":4,"cik":"0002089149","reported_name":"Decheng Capital Management II (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":5,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":6,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":7,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-10-21T00:00:02.000Z","date":"2025-10-17","kind":"sale","planned":false,"acquired":false,"shares":45513,"price":1.76,"value":80102.88,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.73 to $1.80 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). Decheng Capital Management III (Cayman), LLC (\"GP III\") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1518893,"source":{"system":"sec-edgar","filing":"0001231919-25-000335","document":"form4-10202025_111053.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000123191925000335/form4-10202025_111053.xml","form_type":"4"}},{"id":1015826,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74132,"kind":"organization","name":"Decheng Capital Management II (Cayman), LLC","position":4,"cik":"0002089149","reported_name":"Decheng Capital Management II (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":5,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":6,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":7,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-10-21T00:00:02.000Z","date":"2025-10-16","kind":"sale","planned":false,"acquired":false,"shares":85798,"price":1.72,"value":147572.56,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.62 to $1.795 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). Decheng Capital Management III (Cayman), LLC (\"GP III\") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1564406,"source":{"system":"sec-edgar","filing":"0001231919-25-000335","document":"form4-10202025_111053.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000123191925000335/form4-10202025_111053.xml","form_type":"4"}},{"id":1018412,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74132,"kind":"organization","name":"Decheng Capital Management II (Cayman), LLC","position":4,"cik":"0002089149","reported_name":"Decheng Capital Management II (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":5,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":6,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":7,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-10-16T00:07:14.000Z","date":"2025-10-15","kind":"sale","planned":false,"acquired":false,"shares":17960,"price":1.65,"value":29634.0,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.60 to $1.685 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). Decheng Capital Management III (Cayman), LLC (\"GP III\") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1650204,"source":{"system":"sec-edgar","filing":"0001231919-25-000323","document":"form4-10162025_121006.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000123191925000323/form4-10162025_121006.xml","form_type":"4"}},{"id":1018411,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74132,"kind":"organization","name":"Decheng Capital Management II (Cayman), LLC","position":4,"cik":"0002089149","reported_name":"Decheng Capital Management II (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":5,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":6,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":7,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-10-16T00:07:14.000Z","date":"2025-10-14","kind":"sale","planned":false,"acquired":false,"shares":28495,"price":1.65,"value":47016.75,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.62 to $1.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). Decheng Capital Management III (Cayman), LLC (\"GP III\") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1668164,"source":{"system":"sec-edgar","filing":"0001231919-25-000323","document":"form4-10162025_121006.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000123191925000323/form4-10162025_121006.xml","form_type":"4"}},{"id":1018410,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74132,"kind":"organization","name":"Decheng Capital Management II (Cayman), LLC","position":4,"cik":"0002089149","reported_name":"Decheng Capital Management II (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":5,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":6,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":7,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-10-16T00:07:14.000Z","date":"2025-10-13","kind":"sale","planned":false,"acquired":false,"shares":107361,"price":1.7,"value":182513.7,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.69 to $1.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). Decheng Capital Management III (Cayman), LLC (\"GP III\") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1696659,"source":{"system":"sec-edgar","filing":"0001231919-25-000323","document":"form4-10162025_121006.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000123191925000323/form4-10162025_121006.xml","form_type":"4"}},{"id":1020226,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74132,"kind":"organization","name":"Decheng Capital Management II (Cayman), LLC","position":4,"cik":"0002089149","reported_name":"Decheng Capital Management II (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":5,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":6,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":7,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-10-10T21:58:02.000Z","date":"2025-10-10","kind":"sale","planned":false,"acquired":false,"shares":2390,"price":1.77,"value":4230.3,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.73 to $1.83 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). Decheng Capital Management III (Cayman), LLC (\"GP III\") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1804020,"source":{"system":"sec-edgar","filing":"0001231919-25-000308","document":"form4-10102025_091053.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000123191925000308/form4-10102025_091053.xml","form_type":"4"}},{"id":1020225,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74132,"kind":"organization","name":"Decheng Capital Management II (Cayman), LLC","position":4,"cik":"0002089149","reported_name":"Decheng Capital Management II (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":5,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":6,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":7,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-10-10T21:58:02.000Z","date":"2025-10-09","kind":"sale","planned":false,"acquired":false,"shares":3979,"price":1.81,"value":7201.99,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.79 to $1.84 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). Decheng Capital Management III (Cayman), LLC (\"GP III\") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1806410,"source":{"system":"sec-edgar","filing":"0001231919-25-000308","document":"form4-10102025_091053.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000123191925000308/form4-10102025_091053.xml","form_type":"4"}},{"id":1020224,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74132,"kind":"organization","name":"Decheng Capital Management II (Cayman), LLC","position":4,"cik":"0002089149","reported_name":"Decheng Capital Management II (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":5,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":6,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":7,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-10-10T21:58:02.000Z","date":"2025-10-08","kind":"sale","planned":false,"acquired":false,"shares":7507,"price":1.77,"value":13287.39,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.74 to $1.805 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). Decheng Capital Management III (Cayman), LLC (\"GP III\") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1810389,"source":{"system":"sec-edgar","filing":"0001231919-25-000308","document":"form4-10102025_091053.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000123191925000308/form4-10102025_091053.xml","form_type":"4"}},{"id":1022148,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74132,"kind":"organization","name":"Decheng Capital Management II (Cayman), LLC","position":4,"cik":"0002089149","reported_name":"Decheng Capital Management II (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":5,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":6,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":7,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-10-07T22:14:58.000Z","date":"2025-10-07","kind":"sale","planned":false,"acquired":false,"shares":2100,"price":1.79,"value":3759.0,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.74 to $1.80 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). Decheng Capital Management III (Cayman), LLC (\"GP III\") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1817896,"source":{"system":"sec-edgar","filing":"0001231919-25-000292","document":"form4-10072025_101049.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000123191925000292/form4-10072025_101049.xml","form_type":"4"}},{"id":1022147,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74132,"kind":"organization","name":"Decheng Capital Management II (Cayman), LLC","position":4,"cik":"0002089149","reported_name":"Decheng Capital Management II (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":5,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":6,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":7,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-10-07T22:14:58.000Z","date":"2025-10-06","kind":"sale","planned":false,"acquired":false,"shares":17500,"price":1.78,"value":31150.0,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.73 to $1.7879 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). Decheng Capital Management III (Cayman), LLC (\"GP III\") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1819996,"source":{"system":"sec-edgar","filing":"0001231919-25-000292","document":"form4-10072025_101049.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000123191925000292/form4-10072025_101049.xml","form_type":"4"}},{"id":1022146,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74132,"kind":"organization","name":"Decheng Capital Management II (Cayman), LLC","position":4,"cik":"0002089149","reported_name":"Decheng Capital Management II (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":5,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":6,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":7,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-10-07T22:14:58.000Z","date":"2025-10-03","kind":"sale","planned":false,"acquired":false,"shares":600,"price":1.76,"value":1056.0,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.73 to $1.79 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). Decheng Capital Management III (Cayman), LLC (\"GP III\") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1837496,"source":{"system":"sec-edgar","filing":"0001231919-25-000292","document":"form4-10072025_101049.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000123191925000292/form4-10072025_101049.xml","form_type":"4"}},{"id":1027131,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74132,"kind":"organization","name":"Decheng Capital Management II (Cayman), LLC","position":4,"cik":"0002089149","reported_name":"Decheng Capital Management II (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":5,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":6,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":7,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-10-03T00:51:46.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":600,"price":1.73,"value":1038.0,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.72 to $1.74 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). Decheng Capital Management III (Cayman), LLC (\"GP III\") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1838096,"source":{"system":"sec-edgar","filing":"0001231919-25-000278","document":"form4-10032025_121037.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000123191925000278/form4-10032025_121037.xml","form_type":"4"}},{"id":1027130,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74132,"kind":"organization","name":"Decheng Capital Management II (Cayman), LLC","position":4,"cik":"0002089149","reported_name":"Decheng Capital Management II (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":5,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":6,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":7,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-10-03T00:51:46.000Z","date":"2025-10-01","kind":"sale","planned":false,"acquired":false,"shares":2601,"price":1.8,"value":4681.8,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.785 to $1.81 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). Decheng Capital Management III (Cayman), LLC (\"GP III\") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1838696,"source":{"system":"sec-edgar","filing":"0001231919-25-000278","document":"form4-10032025_121037.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000123191925000278/form4-10032025_121037.xml","form_type":"4"}},{"id":1027129,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74132,"kind":"organization","name":"Decheng Capital Management II (Cayman), LLC","position":4,"cik":"0002089149","reported_name":"Decheng Capital Management II (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":5,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":6,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":7,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-10-03T00:51:46.000Z","date":"2025-09-30","kind":"sale","planned":false,"acquired":false,"shares":4464,"price":1.81,"value":8079.84,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.80 to $1.83 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). Decheng Capital Management III (Cayman), LLC (\"GP III\") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1841297,"source":{"system":"sec-edgar","filing":"0001231919-25-000278","document":"form4-10032025_121037.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000123191925000278/form4-10032025_121037.xml","form_type":"4"}},{"id":1031165,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-09-30T00:06:37.000Z","date":"2025-09-29","kind":"sale","planned":false,"acquired":false,"shares":500,"price":1.75,"value":875.0,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.72 to $1.76 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). Decheng Capital Management III (Cayman), LLC (\"GP III\") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1845761,"source":{"system":"sec-edgar","filing":"0001231919-25-000258","document":"form4-09302025_120929.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000123191925000258/form4-09302025_120929.xml","form_type":"4"}},{"id":1031164,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-09-30T00:06:37.000Z","date":"2025-09-26","kind":"sale","planned":false,"acquired":false,"shares":600,"price":1.68,"value":1008.0,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.65 to $1.73 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). Decheng Capital Management III (Cayman), LLC (\"GP III\") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1846261,"source":{"system":"sec-edgar","filing":"0001231919-25-000258","document":"form4-09302025_120929.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000123191925000258/form4-09302025_120929.xml","form_type":"4"}},{"id":1031163,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-09-30T00:06:37.000Z","date":"2025-09-25","kind":"sale","planned":false,"acquired":false,"shares":700,"price":1.66,"value":1162.0,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.64 to $1.67 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). Decheng Capital Management III (Cayman), LLC (\"GP III\") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1846861,"source":{"system":"sec-edgar","filing":"0001231919-25-000258","document":"form4-09302025_120929.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000123191925000258/form4-09302025_120929.xml","form_type":"4"}},{"id":1033011,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-09-24T22:49:10.000Z","date":"2025-09-24","kind":"sale","planned":false,"acquired":false,"shares":2256,"price":1.68,"value":3790.08,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.67 to $1.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). Decheng Capital Management III (Cayman), LLC (\"GP III\") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1847561,"source":{"system":"sec-edgar","filing":"0001231919-25-000244","document":"form4-09242025_100902.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000123191925000244/form4-09242025_100902.xml","form_type":"4"}},{"id":1033010,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-09-24T22:49:10.000Z","date":"2025-09-23","kind":"sale","planned":false,"acquired":false,"shares":4106,"price":1.72,"value":7062.32,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.65 to $1.80 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). Decheng Capital Management III (Cayman), LLC (\"GP III\") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1849817,"source":{"system":"sec-edgar","filing":"0001231919-25-000244","document":"form4-09242025_100902.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000123191925000244/form4-09242025_100902.xml","form_type":"4"}},{"id":1033009,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-09-24T22:49:10.000Z","date":"2025-09-22","kind":"sale","planned":false,"acquired":false,"shares":5410,"price":1.83,"value":9900.3,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.75 to $1.89 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). Decheng Capital Management III (Cayman), LLC (\"GP III\") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1853923,"source":{"system":"sec-edgar","filing":"0001231919-25-000244","document":"form4-09242025_100902.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000123191925000244/form4-09242025_100902.xml","form_type":"4"}},{"id":1035524,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-09-19T22:03:12.000Z","date":"2025-09-19","kind":"sale","planned":false,"acquired":false,"shares":3656,"price":1.79,"value":6544.24,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.72 to $1.85 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). Decheng Capital Management III (Cayman), LLC (\"GP III\") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1859333,"source":{"system":"sec-edgar","filing":"0001231919-25-000221","document":"form4-09192025_100903.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000123191925000221/form4-09192025_100903.xml","form_type":"4"}},{"id":1035523,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-09-19T22:03:12.000Z","date":"2025-09-18","kind":"sale","planned":false,"acquired":false,"shares":5307,"price":1.74,"value":9234.18,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.72 to $1.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). Decheng Capital Management III (Cayman), LLC (\"GP III\") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1862989,"source":{"system":"sec-edgar","filing":"0001231919-25-000221","document":"form4-09192025_100903.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000123191925000221/form4-09192025_100903.xml","form_type":"4"}},{"id":1035522,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-09-19T22:03:12.000Z","date":"2025-09-17","kind":"sale","planned":false,"acquired":false,"shares":2304,"price":1.83,"value":4216.32,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.80 to $1.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). Decheng Capital Management III (Cayman), LLC (\"GP III\") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1868296,"source":{"system":"sec-edgar","filing":"0001231919-25-000221","document":"form4-09192025_100903.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000123191925000221/form4-09192025_100903.xml","form_type":"4"}},{"id":1039294,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-09-16T23:45:49.000Z","date":"2025-09-16","kind":"sale","planned":false,"acquired":false,"shares":840,"price":1.88,"value":1579.2,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.86 to $1.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). Decheng Capital Management III (Cayman), LLC (\"GP III\") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1870600,"source":{"system":"sec-edgar","filing":"0001736814-25-000007","document":"form4-09162025_110941.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000173681425000007/form4-09162025_110941.xml","form_type":"4"}},{"id":1039293,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-09-16T23:45:49.000Z","date":"2025-09-15","kind":"sale","planned":false,"acquired":false,"shares":2570,"price":1.84,"value":4728.8,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.77 to $1.87 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). Decheng Capital Management III (Cayman), LLC (\"GP III\") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1871440,"source":{"system":"sec-edgar","filing":"0001736814-25-000007","document":"form4-09162025_110941.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000173681425000007/form4-09162025_110941.xml","form_type":"4"}},{"id":1039292,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-09-16T23:45:49.000Z","date":"2025-09-12","kind":"sale","planned":false,"acquired":false,"shares":700,"price":1.85,"value":1295.0,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.83 to $1.87 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). Decheng Capital Management III (Cayman), LLC (\"GP III\") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1874010,"source":{"system":"sec-edgar","filing":"0001736814-25-000007","document":"form4-09162025_110941.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000173681425000007/form4-09162025_110941.xml","form_type":"4"}},{"id":1042793,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-09-11T23:43:40.000Z","date":"2025-09-11","kind":"sale","planned":false,"acquired":false,"shares":3820,"price":1.9,"value":7258.0,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.87 to $1.94 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). Decheng Capital Management III (Cayman), LLC (\"GP III\") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1874710,"source":{"system":"sec-edgar","filing":"0001415889-25-024317","document":"form4-09112025_110935.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000141588925024317/form4-09112025_110935.xml","form_type":"4"}},{"id":1042792,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-09-11T23:43:40.000Z","date":"2025-09-10","kind":"sale","planned":false,"acquired":false,"shares":8176,"price":1.93,"value":15779.68,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.90 to $2.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). Decheng Capital Management III (Cayman), LLC (\"GP III\") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1878530,"source":{"system":"sec-edgar","filing":"0001415889-25-024317","document":"form4-09112025_110935.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000141588925024317/form4-09112025_110935.xml","form_type":"4"}},{"id":1042791,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-09-11T23:43:40.000Z","date":"2025-09-09","kind":"sale","planned":false,"acquired":false,"shares":9050,"price":1.97,"value":17828.5,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.90 to $2.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). Decheng Capital Management III (Cayman), LLC (\"GP III\") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1886706,"source":{"system":"sec-edgar","filing":"0001415889-25-024317","document":"form4-09112025_110935.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000141588925024317/form4-09112025_110935.xml","form_type":"4"}},{"id":1045794,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-09-08T22:55:36.000Z","date":"2025-09-08","kind":"sale","planned":false,"acquired":false,"shares":7090,"price":1.93,"value":13683.7,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.79 to $1.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). Decheng Capital Management III (Cayman), LLC (\"GP III\") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1895756,"source":{"system":"sec-edgar","filing":"0001415889-25-023907","document":"form4-09082025_100931.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000141588925023907/form4-09082025_100931.xml","form_type":"4"}},{"id":1045793,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-09-08T22:55:36.000Z","date":"2025-09-05","kind":"sale","planned":false,"acquired":false,"shares":1106,"price":1.86,"value":2057.16,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.82 to $1.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). Decheng Capital Management III (Cayman), LLC (\"GP III\") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1902846,"source":{"system":"sec-edgar","filing":"0001415889-25-023907","document":"form4-09082025_100931.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000141588925023907/form4-09082025_100931.xml","form_type":"4"}},{"id":1045792,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-09-08T22:55:36.000Z","date":"2025-09-04","kind":"sale","planned":false,"acquired":false,"shares":803,"price":1.82,"value":1461.46,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.79 to $1.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). Decheng Capital Management III (Cayman), LLC (\"GP III\") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1903952,"source":{"system":"sec-edgar","filing":"0001415889-25-023907","document":"form4-09082025_100931.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000141588925023907/form4-09082025_100931.xml","form_type":"4"}},{"id":1049541,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-09-03T23:57:06.000Z","date":"2025-09-03","kind":"sale","planned":false,"acquired":false,"shares":1270,"price":1.81,"value":2298.7,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.79 to $1.84 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). Decheng Capital Management III (Cayman), LLC (\"GP III\") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1904755,"source":{"system":"sec-edgar","filing":"0001415889-25-023607","document":"form4-09032025_110901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000141588925023607/form4-09032025_110901.xml","form_type":"4"}},{"id":1049540,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-09-03T23:57:06.000Z","date":"2025-09-02","kind":"sale","planned":false,"acquired":false,"shares":2800,"price":1.78,"value":4984.0,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.67 to $1.84 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). Decheng Capital Management III (Cayman), LLC (\"GP III\") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1906025,"source":{"system":"sec-edgar","filing":"0001415889-25-023607","document":"form4-09032025_110901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000141588925023607/form4-09032025_110901.xml","form_type":"4"}},{"id":1049539,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-09-03T23:57:06.000Z","date":"2025-08-29","kind":"sale","planned":false,"acquired":false,"shares":800,"price":1.74,"value":1392.0,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.72 to $1.80 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). Decheng Capital Management III (Cayman), LLC (\"GP III\") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1908825,"source":{"system":"sec-edgar","filing":"0001415889-25-023607","document":"form4-09032025_110901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000141588925023607/form4-09032025_110901.xml","form_type":"4"}},{"id":1053551,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-08-29T00:39:13.000Z","date":"2025-08-28","kind":"sale","planned":false,"acquired":false,"shares":809,"price":1.81,"value":1464.29,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.79 to $1.82 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). Decheng Capital Management III (Cayman), LLC (\"GP III\") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1909625,"source":{"system":"sec-edgar","filing":"0001415889-25-023258","document":"form4-08292025_120807.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000141588925023258/form4-08292025_120807.xml","form_type":"4"}},{"id":1053550,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-08-29T00:39:13.000Z","date":"2025-08-27","kind":"sale","planned":false,"acquired":false,"shares":1300,"price":1.78,"value":2314.0,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.75 to $1.82 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). Decheng Capital Management III (Cayman), LLC (\"GP III\") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1910434,"source":{"system":"sec-edgar","filing":"0001415889-25-023258","document":"form4-08292025_120807.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000141588925023258/form4-08292025_120807.xml","form_type":"4"}},{"id":1053549,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-08-29T00:39:13.000Z","date":"2025-08-26","kind":"sale","planned":false,"acquired":false,"shares":2000,"price":1.79,"value":3580.0,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.76 to $1.84 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). Decheng Capital Management III (Cayman), LLC (\"GP III\") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1911734,"source":{"system":"sec-edgar","filing":"0001415889-25-023258","document":"form4-08292025_120807.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000141588925023258/form4-08292025_120807.xml","form_type":"4"}},{"id":1056798,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-08-25T23:46:54.000Z","date":"2025-08-25","kind":"sale","planned":false,"acquired":false,"shares":300,"price":1.77,"value":531.0,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.75 to $1.78 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). Decheng Capital Management III (Cayman), LLC (\"GP III\") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1913734,"source":{"system":"sec-edgar","filing":"0001415889-25-022967","document":"form4-08252025_110849.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000141588925022967/form4-08252025_110849.xml","form_type":"4"}},{"id":1056797,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-08-25T23:46:54.000Z","date":"2025-08-22","kind":"sale","planned":false,"acquired":false,"shares":2376,"price":1.75,"value":4158.0,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.75 to $1.77 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). Decheng Capital Management III (Cayman), LLC (\"GP III\") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1914034,"source":{"system":"sec-edgar","filing":"0001415889-25-022967","document":"form4-08252025_110849.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000141588925022967/form4-08252025_110849.xml","form_type":"4"}},{"id":1056796,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-08-25T23:46:54.000Z","date":"2025-08-21","kind":"sale","planned":false,"acquired":false,"shares":3034,"price":1.79,"value":5430.86,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.74 to $1.86 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). Decheng Capital Management III (Cayman), LLC (\"GP III\") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1916410,"source":{"system":"sec-edgar","filing":"0001415889-25-022967","document":"form4-08252025_110849.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000141588925022967/form4-08252025_110849.xml","form_type":"4"}},{"id":1060206,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-08-20T22:35:28.000Z","date":"2025-08-20","kind":"sale","planned":false,"acquired":false,"shares":3456,"price":1.74,"value":6013.44,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.72 to $1.76 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). Decheng Capital Management III (Cayman), LLC (\"GP III\") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1919444,"source":{"system":"sec-edgar","filing":"0001415889-25-022532","document":"form4-08202025_100823.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000141588925022532/form4-08202025_100823.xml","form_type":"4"}},{"id":1060205,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-08-20T22:35:28.000Z","date":"2025-08-19","kind":"sale","planned":false,"acquired":false,"shares":3604,"price":1.77,"value":6379.08,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.75 to $1.85 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). Decheng Capital Management III (Cayman), LLC (\"GP III\") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1922900,"source":{"system":"sec-edgar","filing":"0001415889-25-022532","document":"form4-08202025_100823.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000141588925022532/form4-08202025_100823.xml","form_type":"4"}},{"id":1060204,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-08-20T22:35:28.000Z","date":"2025-08-18","kind":"sale","planned":false,"acquired":false,"shares":47668,"price":2.03,"value":96766.04,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.85 to $2.04 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). Decheng Capital Management III (Cayman), LLC (\"GP III\") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1926504,"source":{"system":"sec-edgar","filing":"0001415889-25-022532","document":"form4-08202025_100823.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000141588925022532/form4-08202025_100823.xml","form_type":"4"}},{"id":1065270,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-08-15T23:11:59.000Z","date":"2025-08-15","kind":"sale","planned":false,"acquired":false,"shares":2900,"price":2,"value":5800.0,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.00 to $2.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). Decheng Capital Management III (Cayman), LLC (\"GP III\") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1974172,"source":{"system":"sec-edgar","filing":"0001415889-25-022119","document":"form4-08152025_110853.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000141588925022119/form4-08152025_110853.xml","form_type":"4"}},{"id":1065269,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-08-15T23:11:59.000Z","date":"2025-08-14","kind":"sale","planned":false,"acquired":false,"shares":2000,"price":2,"value":4000.0,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.00 to $2.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares vat each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). Decheng Capital Management III (Cayman), LLC (\"GP III\") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1977072,"source":{"system":"sec-edgar","filing":"0001415889-25-022119","document":"form4-08152025_110853.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000141588925022119/form4-08152025_110853.xml","form_type":"4"}},{"id":1070145,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-08-11T21:07:18.000Z","date":"2025-08-04","kind":"sale","planned":false,"acquired":false,"shares":2196,"price":2.18,"value":4787.28,"ownership":{"direct":false,"nature":"By Decheng Capital Global Healthcare Fund (Master), LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP (\"Healthcare\"). Decheng Capital Global Healthcare GP, LLC (\"Healthcare GP\") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":891734,"source":{"system":"sec-edgar","filing":"0001415889-25-021441","document":"form4-08112025_090812.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000141588925021441/form4-08112025_090812.xml","form_type":"4"}},{"id":1070144,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-08-11T21:07:18.000Z","date":"2025-07-18","kind":"sale","planned":false,"acquired":false,"shares":900,"price":2.2,"value":1980.0,"ownership":{"direct":false,"nature":"By Decheng Capital Global Healthcare Fund (Master), LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP (\"Healthcare\"). Decheng Capital Global Healthcare GP, LLC (\"Healthcare GP\") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":893930,"source":{"system":"sec-edgar","filing":"0001415889-25-021441","document":"form4-08112025_090812.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000141588925021441/form4-08112025_090812.xml","form_type":"4"}},{"id":1070143,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-08-11T21:07:18.000Z","date":"2025-07-17","kind":"sale","planned":false,"acquired":false,"shares":20572,"price":2.19,"value":45052.68,"ownership":{"direct":false,"nature":"By Decheng Capital Global Healthcare Fund (Master), LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP (\"Healthcare\"). Decheng Capital Global Healthcare GP, LLC (\"Healthcare GP\") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":894830,"source":{"system":"sec-edgar","filing":"0001415889-25-021441","document":"form4-08112025_090812.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000141588925021441/form4-08112025_090812.xml","form_type":"4"}},{"id":1070142,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-08-11T21:07:18.000Z","date":"2025-07-16","kind":"sale","planned":false,"acquired":false,"shares":5396,"price":2.24,"value":12087.04,"ownership":{"direct":false,"nature":"By Decheng Capital Global Healthcare Fund (Master), LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP (\"Healthcare\"). Decheng Capital Global Healthcare GP, LLC (\"Healthcare GP\") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":915402,"source":{"system":"sec-edgar","filing":"0001415889-25-021441","document":"form4-08112025_090812.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000141588925021441/form4-08112025_090812.xml","form_type":"4"}},{"id":1070141,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-08-11T21:07:18.000Z","date":"2025-07-15","kind":"sale","planned":false,"acquired":false,"shares":2152,"price":2.28,"value":4906.56,"ownership":{"direct":false,"nature":"By Decheng Capital Global Healthcare Fund (Master), LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP (\"Healthcare\"). Decheng Capital Global Healthcare GP, LLC (\"Healthcare GP\") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":920798,"source":{"system":"sec-edgar","filing":"0001415889-25-021441","document":"form4-08112025_090812.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000141588925021441/form4-08112025_090812.xml","form_type":"4"}},{"id":1070140,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-08-11T21:07:18.000Z","date":"2025-07-14","kind":"sale","planned":false,"acquired":false,"shares":801,"price":2.29,"value":1834.29,"ownership":{"direct":false,"nature":"By Decheng Capital Global Healthcare Fund (Master), LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP (\"Healthcare\"). Decheng Capital Global Healthcare GP, LLC (\"Healthcare GP\") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":922950,"source":{"system":"sec-edgar","filing":"0001415889-25-021441","document":"form4-08112025_090812.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000141588925021441/form4-08112025_090812.xml","form_type":"4"}},{"id":1070139,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-08-11T21:07:18.000Z","date":"2025-07-11","kind":"sale","planned":false,"acquired":false,"shares":246,"price":2.29,"value":563.34,"ownership":{"direct":false,"nature":"By Decheng Capital Global Healthcare Fund (Master), LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP (\"Healthcare\"). Decheng Capital Global Healthcare GP, LLC (\"Healthcare GP\") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":923751,"source":{"system":"sec-edgar","filing":"0001415889-25-021441","document":"form4-08112025_090812.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000141588925021441/form4-08112025_090812.xml","form_type":"4"}},{"id":1070138,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-08-11T21:07:18.000Z","date":"2025-07-10","kind":"sale","planned":false,"acquired":false,"shares":768,"price":2.28,"value":1751.04,"ownership":{"direct":false,"nature":"By Decheng Capital Global Healthcare Fund (Master), LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP (\"Healthcare\"). Decheng Capital Global Healthcare GP, LLC (\"Healthcare GP\") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":923997,"source":{"system":"sec-edgar","filing":"0001415889-25-021441","document":"form4-08112025_090812.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000141588925021441/form4-08112025_090812.xml","form_type":"4"}},{"id":1070137,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-08-11T21:07:18.000Z","date":"2025-07-09","kind":"sale","planned":false,"acquired":false,"shares":252,"price":2.27,"value":572.04,"ownership":{"direct":false,"nature":"By Decheng Capital Global Healthcare Fund (Master), LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP (\"Healthcare\"). Decheng Capital Global Healthcare GP, LLC (\"Healthcare GP\") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":924765,"source":{"system":"sec-edgar","filing":"0001415889-25-021441","document":"form4-08112025_090812.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000141588925021441/form4-08112025_090812.xml","form_type":"4"}},{"id":1070136,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-08-11T21:07:18.000Z","date":"2025-07-08","kind":"sale","planned":false,"acquired":false,"shares":9059,"price":2.29,"value":20745.11,"ownership":{"direct":false,"nature":"By Decheng Capital Global Healthcare Fund (Master), LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP (\"Healthcare\"). Decheng Capital Global Healthcare GP, LLC (\"Healthcare GP\") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":925017,"source":{"system":"sec-edgar","filing":"0001415889-25-021441","document":"form4-08112025_090812.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000141588925021441/form4-08112025_090812.xml","form_type":"4"}},{"id":1070135,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-08-11T21:07:18.000Z","date":"2025-07-02","kind":"sale","planned":false,"acquired":false,"shares":324,"price":2.42,"value":784.08,"ownership":{"direct":false,"nature":"By Decheng Capital Global Healthcare Fund (Master), LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP (\"Healthcare\"). Decheng Capital Global Healthcare GP, LLC (\"Healthcare GP\") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":934076,"source":{"system":"sec-edgar","filing":"0001415889-25-021441","document":"form4-08112025_090812.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000141588925021441/form4-08112025_090812.xml","form_type":"4"}},{"id":1070134,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-08-11T21:07:18.000Z","date":"2025-07-01","kind":"sale","planned":false,"acquired":false,"shares":600,"price":2.43,"value":1458.0,"ownership":{"direct":false,"nature":"By Decheng Capital Global Healthcare Fund (Master), LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP (\"Healthcare\"). Decheng Capital Global Healthcare GP, LLC (\"Healthcare GP\") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":934400,"source":{"system":"sec-edgar","filing":"0001415889-25-021441","document":"form4-08112025_090812.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000141588925021441/form4-08112025_090812.xml","form_type":"4"}},{"id":1070133,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-08-11T21:07:18.000Z","date":"2025-06-23","kind":"sale","planned":false,"acquired":false,"shares":1700,"price":3.09,"value":5253.0,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $3.06 to $3.19 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund II, L.P. (\"Fund II\"). Decheng Capital Management II (Cayman), LLC (\"GP II\") is the general partner of Fund II. Dr. Cui is the manager of GP II. Each of Fund II, GP II and Dr. Cui may be deemed to beneficially own the securities held by Fund II. Each of GP II and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1617409,"source":{"system":"sec-edgar","filing":"0001415889-25-021441","document":"form4-08112025_090812.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000141588925021441/form4-08112025_090812.xml","form_type":"4"}},{"id":1070132,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-08-11T21:07:18.000Z","date":"2025-06-20","kind":"sale","planned":false,"acquired":false,"shares":225217,"price":3.16,"value":711685.72,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $3.05 to $3.27 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund II, L.P. (\"Fund II\"). Decheng Capital Management II (Cayman), LLC (\"GP II\") is the general partner of Fund II. Dr. Cui is the manager of GP II. Each of Fund II, GP II and Dr. Cui may be deemed to beneficially own the securities held by Fund II. Each of GP II and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1619109,"source":{"system":"sec-edgar","filing":"0001415889-25-021441","document":"form4-08112025_090812.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000141588925021441/form4-08112025_090812.xml","form_type":"4"}},{"id":1070131,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-08-11T21:07:18.000Z","date":"2025-06-20","kind":"sale","planned":false,"acquired":false,"shares":60000,"price":3.11,"value":186600.0,"ownership":{"direct":false,"nature":"By Decheng Capital Global Healthcare Fund (Master), LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP (\"Healthcare\"). Decheng Capital Global Healthcare GP, LLC (\"Healthcare GP\") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":935000,"source":{"system":"sec-edgar","filing":"0001415889-25-021441","document":"form4-08112025_090812.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000141588925021441/form4-08112025_090812.xml","form_type":"4"}},{"id":1070130,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-08-11T21:07:18.000Z","date":"2025-06-18","kind":"sale","planned":false,"acquired":false,"shares":59253,"price":3.17,"value":187832.01,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $3.10 to $3.34 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by Decheng Capital China Life Sciences USD Fund II, L.P. (\"Fund II\"). Decheng Capital Management II (Cayman), LLC (\"GP II\") is the general partner of Fund II. Dr. Cui is the manager of GP II. Each of Fund II, GP II and Dr. Cui may be deemed to beneficially own the securities held by Fund II. Each of GP II and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":1844326,"source":{"system":"sec-edgar","filing":"0001415889-25-021441","document":"form4-08112025_090812.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000141588925021441/form4-08112025_090812.xml","form_type":"4"}},{"id":1070129,"issuer":{"id":7539,"kind":"organization","name":"BeyondSpring Inc."},"owners":[{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":1,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":2,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74131,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund II, L.P.","position":3,"cik":"0001650291","reported_name":"Decheng Capital China Life Sciences USD Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":6,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2025-08-11T21:07:18.000Z","date":"2025-06-17","kind":"sale","planned":false,"acquired":false,"shares":5000,"price":3.23,"value":16150.0,"ownership":{"direct":false,"nature":"By Decheng Capital Global Healthcare Fund (Master), LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP (\"Healthcare\"). Decheng Capital Global Healthcare GP, LLC (\"Healthcare GP\") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":995000,"source":{"system":"sec-edgar","filing":"0001415889-25-021441","document":"form4-08112025_090812.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000141588925021441/form4-08112025_090812.xml","form_type":"4"}},{"id":1259804,"issuer":{"id":6598,"kind":"organization","name":"Aardvark Therapeutics, Inc.","symbol":"AARD"},"owners":[{"id":83056,"kind":"organization","name":"Decheng Capital Global Life Sciences Fund IV, L.P.","position":1,"cik":"0001834150","reported_name":"Decheng Capital Global Life Sciences Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83057,"kind":"organization","name":"Decheng Capital Management IV (Cayman), LLC","position":2,"cik":"0001843384","reported_name":"Decheng Capital Management IV (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":3,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":4,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":5,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2025-02-19T22:44:41.000Z","date":"2025-02-14","kind":"exercise","planned":false,"acquired":false,"shares":2825337,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Decheng Capital Global Healthcare Fund (Master), LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the \"Issuer\") automatically converted on an 8.474-for-1 basis into shares of the Issuer's common stock (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series C Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the \"Issuer\") automatically converted on an 8.474-for-1 basis into shares of the Issuer's common stock (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series C Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the \"Issuer\") automatically converted on an 8.474-for-1 basis into shares of the Issuer's common stock (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series C Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP (\"Healthcare\"). Decheng Capital Global Healthcare GP, LLC (\"Healthcare GP\") is the general partner of Healthcare. Xiangmin Cui is the indirect managing member and ultimate beneficial owner of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":333412},"source":{"system":"sec-edgar","filing":"0000950170-25-023409","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000095017025023409/ownership.xml","form_type":"4"}},{"id":1259803,"issuer":{"id":6598,"kind":"organization","name":"Aardvark Therapeutics, Inc.","symbol":"AARD"},"owners":[{"id":83056,"kind":"organization","name":"Decheng Capital Global Life Sciences Fund IV, L.P.","position":1,"cik":"0001834150","reported_name":"Decheng Capital Global Life Sciences Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83057,"kind":"organization","name":"Decheng Capital Management IV (Cayman), LLC","position":2,"cik":"0001843384","reported_name":"Decheng Capital Management IV (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":3,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":4,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":5,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2025-02-19T22:44:41.000Z","date":"2025-02-14","kind":"exercise","planned":false,"acquired":false,"shares":19777363,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Decheng Capital Global Life Sciences Fund IV, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series C Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the \"Issuer\") automatically converted on an 8.474-for-1 basis into shares of the Issuer's common stock (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series C Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series C Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the \"Issuer\") automatically converted on an 8.474-for-1 basis into shares of the Issuer's common stock (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series C Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series C Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the \"Issuer\") automatically converted on an 8.474-for-1 basis into shares of the Issuer's common stock (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series C Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital Global Life Sciences Fund IV, L.P. (\"Fund IV\"). Decheng Capital Management IV (Cayman), LLC (\"GP IV\") is the general partner of Fund IV. Xiangmin Cui is the manager of GP IV. Each of Fund IV, GP IV and Dr. Cui may be deemed to beneficially own the securities held by Fund IV. Each of GP IV and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2333887},"source":{"system":"sec-edgar","filing":"0000950170-25-023409","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000095017025023409/ownership.xml","form_type":"4"}},{"id":1259802,"issuer":{"id":6598,"kind":"organization","name":"Aardvark Therapeutics, Inc.","symbol":"AARD"},"owners":[{"id":83056,"kind":"organization","name":"Decheng Capital Global Life Sciences Fund IV, L.P.","position":1,"cik":"0001834150","reported_name":"Decheng Capital Global Life Sciences Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83057,"kind":"organization","name":"Decheng Capital Management IV (Cayman), LLC","position":2,"cik":"0001843384","reported_name":"Decheng Capital Management IV (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":3,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":4,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":5,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-02-19T22:44:41.000Z","date":"2025-02-14","kind":"purchase","planned":false,"acquired":true,"shares":625000,"price":16,"value":10000000.0,"ownership":{"direct":false,"nature":"By Decheng Capital Global Healthcare Fund (Master), LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP (\"Healthcare\"). Decheng Capital Global Healthcare GP, LLC (\"Healthcare GP\") is the general partner of Healthcare. Xiangmin Cui is the indirect managing member and ultimate beneficial owner of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":958412,"source":{"system":"sec-edgar","filing":"0000950170-25-023409","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000095017025023409/ownership.xml","form_type":"4"}},{"id":1259801,"issuer":{"id":6598,"kind":"organization","name":"Aardvark Therapeutics, Inc.","symbol":"AARD"},"owners":[{"id":83056,"kind":"organization","name":"Decheng Capital Global Life Sciences Fund IV, L.P.","position":1,"cik":"0001834150","reported_name":"Decheng Capital Global Life Sciences Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83057,"kind":"organization","name":"Decheng Capital Management IV (Cayman), LLC","position":2,"cik":"0001843384","reported_name":"Decheng Capital Management IV (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":3,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":4,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":5,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-02-19T22:44:41.000Z","date":"2025-02-14","kind":"purchase","planned":false,"acquired":true,"shares":625000,"price":16,"value":10000000.0,"ownership":{"direct":false,"nature":"By Decheng Capital Global Life Sciences Fund IV, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital Global Life Sciences Fund IV, L.P. (\"Fund IV\"). Decheng Capital Management IV (Cayman), LLC (\"GP IV\") is the general partner of Fund IV. Xiangmin Cui is the manager of GP IV. Each of Fund IV, GP IV and Dr. Cui may be deemed to beneficially own the securities held by Fund IV. Each of GP IV and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":2958887,"source":{"system":"sec-edgar","filing":"0000950170-25-023409","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000095017025023409/ownership.xml","form_type":"4"}},{"id":1259800,"issuer":{"id":6598,"kind":"organization","name":"Aardvark Therapeutics, Inc.","symbol":"AARD"},"owners":[{"id":83056,"kind":"organization","name":"Decheng Capital Global Life Sciences Fund IV, L.P.","position":1,"cik":"0001834150","reported_name":"Decheng Capital Global Life Sciences Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83057,"kind":"organization","name":"Decheng Capital Management IV (Cayman), LLC","position":2,"cik":"0001843384","reported_name":"Decheng Capital Management IV (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":3,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":4,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":5,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-02-19T22:44:41.000Z","date":"2025-02-14","kind":"exercise","planned":false,"acquired":true,"shares":333412,"ownership":{"direct":false,"nature":"By Decheng Capital Global Healthcare Fund (Master), LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series C Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the \"Issuer\") automatically converted on an 8.474-for-1 basis into shares of the Issuer's common stock (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series C Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP (\"Healthcare\"). Decheng Capital Global Healthcare GP, LLC (\"Healthcare GP\") is the general partner of Healthcare. Xiangmin Cui is the indirect managing member and ultimate beneficial owner of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":333412,"source":{"system":"sec-edgar","filing":"0000950170-25-023409","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000095017025023409/ownership.xml","form_type":"4"}},{"id":1259799,"issuer":{"id":6598,"kind":"organization","name":"Aardvark Therapeutics, Inc.","symbol":"AARD"},"owners":[{"id":83056,"kind":"organization","name":"Decheng Capital Global Life Sciences Fund IV, L.P.","position":1,"cik":"0001834150","reported_name":"Decheng Capital Global Life Sciences Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83057,"kind":"organization","name":"Decheng Capital Management IV (Cayman), LLC","position":2,"cik":"0001843384","reported_name":"Decheng Capital Management IV (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":3,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":4,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":5,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-02-19T22:44:41.000Z","date":"2025-02-14","kind":"exercise","planned":false,"acquired":true,"shares":2333887,"ownership":{"direct":false,"nature":"By Decheng Capital Global Life Sciences Fund IV, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series C Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the \"Issuer\") automatically converted on an 8.474-for-1 basis into shares of the Issuer's common stock (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series C Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by Decheng Capital Global Life Sciences Fund IV, L.P. (\"Fund IV\"). Decheng Capital Management IV (Cayman), LLC (\"GP IV\") is the general partner of Fund IV. Xiangmin Cui is the manager of GP IV. Each of Fund IV, GP IV and Dr. Cui may be deemed to beneficially own the securities held by Fund IV. Each of GP IV and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":2333887,"source":{"system":"sec-edgar","filing":"0000950170-25-023409","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000095017025023409/ownership.xml","form_type":"4"}},{"id":1414059,"issuer":{"id":4384,"kind":"organization","name":"Nuvation Bio Inc."},"owners":[{"id":44249,"kind":"person","name":"Cui Xiangmin","position":1,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2024-09-05T20:15:06.000Z","date":"2024-09-04","kind":"exercise","planned":false,"acquired":false,"shares":128792,"ownership":{"direct":false,"nature":"By Decheng Anbio Limited"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In accordance with the Certificate of Designation of Preferences, Rights and Limitations of the Series A Non-Voting Convertible Preferred Stock (the \"Series A Preferred Stock\"), these shares of Series A Preferred Stock were automatically converted to Class A common stock based on the conversion ratio described in footnote 5, for no additional consideration, effective as of 5:00 p.m. Eastern time on September 4, 2024, the first business day following the satisfaction of the Convertibility Condition (as defined in footnote 6)."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Received pursuant to the Agreement and Plan of Merger and Reorganization, dated as of March 24, 2024, by and among the Issuer, AnHeart Therapeutics Ltd. (\"AnHeart\"), Artemis Merger Sub I, Ltd., a wholly owned subsidiary of the Issuer (\"Merger Sub I\"), and Artemis Merger Sub II, Ltd., a wholly owned subsidiary of the Issuer (\"Merger Sub II\"), whereby Merger Sub I merged with and into AnHeart, with AnHeart surviving such merger as a direct, wholly owned subsidiary of the Issuer (the \"First Merger\"). Immediately following the First Merger, AnHeart, as the surviving company of the First Merger, merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Upon satisfaction of the Convertibility Condition, each share of Series A Preferred Stock became automatically convertible into 100 shares of Class A common stock, for no additional consideration, effective as of 5:00 p.m. Eastern time on September 4, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Upon satisfaction of the Convertibility Condition, each share of Series A Preferred Stock became automatically convertible into 100 shares of Class A common stock, for no additional consideration, effective as of 5:00 p.m. Eastern time on September 4, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are owned directly by Decheng Anbio Limited (\"SPV\"). The Reporting Person is a director of SPV. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Class A Common Stock","underlying_shares":12879200},"source":{"system":"sec-edgar","filing":"0001415889-24-022899","document":"form4-09052024_040901.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1811063/000141588924022899/form4-09052024_040901.xml","form_type":"4"}},{"id":1414058,"issuer":{"id":4384,"kind":"organization","name":"Nuvation Bio Inc."},"owners":[{"id":44249,"kind":"person","name":"Cui Xiangmin","position":1,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2024-09-05T20:15:06.000Z","date":"2024-09-04","kind":"exercise","planned":false,"acquired":false,"shares":51579,"ownership":{"direct":false,"nature":"By Decheng Capital Global Healthcare Fund (Master), LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In accordance with the Certificate of Designation of Preferences, Rights and Limitations of the Series A Non-Voting Convertible Preferred Stock (the \"Series A Preferred Stock\"), these shares of Series A Preferred Stock were automatically converted to Class A common stock based on the conversion ratio described in footnote 5, for no additional consideration, effective as of 5:00 p.m. Eastern time on September 4, 2024, the first business day following the satisfaction of the Convertibility Condition (as defined in footnote 6)."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Received pursuant to the Agreement and Plan of Merger and Reorganization, dated as of March 24, 2024, by and among the Issuer, AnHeart Therapeutics Ltd. (\"AnHeart\"), Artemis Merger Sub I, Ltd., a wholly owned subsidiary of the Issuer (\"Merger Sub I\"), and Artemis Merger Sub II, Ltd., a wholly owned subsidiary of the Issuer (\"Merger Sub II\"), whereby Merger Sub I merged with and into AnHeart, with AnHeart surviving such merger as a direct, wholly owned subsidiary of the Issuer (the \"First Merger\"). Immediately following the First Merger, AnHeart, as the surviving company of the First Merger, merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Upon satisfaction of the Convertibility Condition, each share of Series A Preferred Stock became automatically convertible into 100 shares of Class A common stock, for no additional consideration, effective as of 5:00 p.m. Eastern time on September 4, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Upon satisfaction of the Convertibility Condition, each share of Series A Preferred Stock became automatically convertible into 100 shares of Class A common stock, for no additional consideration, effective as of 5:00 p.m. Eastern time on September 4, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are owned directly by Decheng Capital Global Healthcare Fund (Master), LP (\"Healthcare\"). The Reporting Person is the indirect managing member and ultimate beneficial owner of Decheng Capital Global Healthcare GP, LLC, the general partner of Healthcare. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Class A Common Stock","underlying_shares":5157900},"source":{"system":"sec-edgar","filing":"0001415889-24-022899","document":"form4-09052024_040901.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1811063/000141588924022899/form4-09052024_040901.xml","form_type":"4"}},{"id":1414057,"issuer":{"id":4384,"kind":"organization","name":"Nuvation Bio Inc."},"owners":[{"id":44249,"kind":"person","name":"Cui Xiangmin","position":1,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2024-09-05T20:15:06.000Z","date":"2024-09-04","kind":"exercise","planned":false,"acquired":false,"shares":9671,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In accordance with the Certificate of Designation of Preferences, Rights and Limitations of the Series A Non-Voting Convertible Preferred Stock (the \"Series A Preferred Stock\"), these shares of Series A Preferred Stock were automatically converted to Class A common stock based on the conversion ratio described in footnote 5, for no additional consideration, effective as of 5:00 p.m. Eastern time on September 4, 2024, the first business day following the satisfaction of the Convertibility Condition (as defined in footnote 6)."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Received pursuant to the Agreement and Plan of Merger and Reorganization, dated as of March 24, 2024, by and among the Issuer, AnHeart Therapeutics Ltd. (\"AnHeart\"), Artemis Merger Sub I, Ltd., a wholly owned subsidiary of the Issuer (\"Merger Sub I\"), and Artemis Merger Sub II, Ltd., a wholly owned subsidiary of the Issuer (\"Merger Sub II\"), whereby Merger Sub I merged with and into AnHeart, with AnHeart surviving such merger as a direct, wholly owned subsidiary of the Issuer (the \"First Merger\"). Immediately following the First Merger, AnHeart, as the surviving company of the First Merger, merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Upon satisfaction of the Convertibility Condition, each share of Series A Preferred Stock became automatically convertible into 100 shares of Class A common stock, for no additional consideration, effective as of 5:00 p.m. Eastern time on September 4, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Upon satisfaction of the Convertibility Condition, each share of Series A Preferred Stock became automatically convertible into 100 shares of Class A common stock, for no additional consideration, effective as of 5:00 p.m. Eastern time on September 4, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are owned directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). The Reporting Person is the manager of Decheng Capital Management III (Cayman), LLC, the general partner of Fund III. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Class A Common Stock","underlying_shares":967100},"source":{"system":"sec-edgar","filing":"0001415889-24-022899","document":"form4-09052024_040901.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1811063/000141588924022899/form4-09052024_040901.xml","form_type":"4"}},{"id":1414056,"issuer":{"id":4384,"kind":"organization","name":"Nuvation Bio Inc."},"owners":[{"id":44249,"kind":"person","name":"Cui Xiangmin","position":1,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (Right to Buy)","published_at":"2024-09-05T20:15:06.000Z","date":"2024-09-03","kind":"grant","planned":false,"acquired":true,"shares":437834,"ownership":{"direct":false,"nature":"By Decheng Anbio Limited"},"footnotes":[{"field":"date","element":"transactionDate","label":"F6","text":"The Series A Preferred Stock and Warrants were originally acquired on April 9, 2024. Upon issuance, the Series A Preferred Stock was not convertible into, and the Warrants were not exercisable for, Class A common stock until the Issuer's stockholders approved the issuance of the Class A common stock issuable upon conversion of the Series A Preferred Stock and exercise of Warrants (the \"Convertibility Condition\"). Because of the Convertibility Condition, the Series A Preferred Stock and the Warrants were not considered derivative securities and were, therefore, not reportable under Section 16 of the Securities Exchange Act, until such condition was satisfied. The Convertibility Condition was satisfied on September 3, 2024."},{"field":"shares","element":"transactionShares","label":"F7","text":"Received pursuant to the Agreement and Plan of Merger and Reorganization, dated as of March 24, 2024, by and among the Issuer, AnHeart Therapeutics Ltd. (\"AnHeart\"), Artemis Merger Sub I, Ltd., a wholly owned subsidiary of the Issuer (\"Merger Sub I\"), and Artemis Merger Sub II, Ltd., a wholly owned subsidiary of the Issuer (\"Merger Sub II\"), whereby Merger Sub I merged with and into AnHeart, with AnHeart surviving such merger as a direct, wholly owned subsidiary of the Issuer (the \"First Merger\"). Immediately following the First Merger, AnHeart, as the surviving company of the First Merger, merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Received pursuant to the Agreement and Plan of Merger and Reorganization, dated as of March 24, 2024, by and among the Issuer, AnHeart Therapeutics Ltd. (\"AnHeart\"), Artemis Merger Sub I, Ltd., a wholly owned subsidiary of the Issuer (\"Merger Sub I\"), and Artemis Merger Sub II, Ltd., a wholly owned subsidiary of the Issuer (\"Merger Sub II\"), whereby Merger Sub I merged with and into AnHeart, with AnHeart surviving such merger as a direct, wholly owned subsidiary of the Issuer (the \"First Merger\"). Immediately following the First Merger, AnHeart, as the surviving company of the First Merger, merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Upon satisfaction of the Convertibility Condition, the Warrants became exercisable for Class A common stock at any time at the option of the holder."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are owned directly by Decheng Anbio Limited (\"SPV\"). The Reporting Person is a director of SPV. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein."}],"balance_after":437834,"derivative":{"exercise_price":11.5,"expiration_date":"2029-04-09","underlying":"Class A Common Stock","underlying_shares":437834},"source":{"system":"sec-edgar","filing":"0001415889-24-022899","document":"form4-09052024_040901.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1811063/000141588924022899/form4-09052024_040901.xml","form_type":"4"}},{"id":1414055,"issuer":{"id":4384,"kind":"organization","name":"Nuvation Bio Inc."},"owners":[{"id":44249,"kind":"person","name":"Cui Xiangmin","position":1,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (Right to Buy)","published_at":"2024-09-05T20:15:06.000Z","date":"2024-09-03","kind":"grant","planned":false,"acquired":true,"shares":175346,"ownership":{"direct":false,"nature":"By Decheng Capital Global Healthcare Fund (Master), LP"},"footnotes":[{"field":"date","element":"transactionDate","label":"F6","text":"The Series A Preferred Stock and Warrants were originally acquired on April 9, 2024. Upon issuance, the Series A Preferred Stock was not convertible into, and the Warrants were not exercisable for, Class A common stock until the Issuer's stockholders approved the issuance of the Class A common stock issuable upon conversion of the Series A Preferred Stock and exercise of Warrants (the \"Convertibility Condition\"). Because of the Convertibility Condition, the Series A Preferred Stock and the Warrants were not considered derivative securities and were, therefore, not reportable under Section 16 of the Securities Exchange Act, until such condition was satisfied. The Convertibility Condition was satisfied on September 3, 2024."},{"field":"shares","element":"transactionShares","label":"F7","text":"Received pursuant to the Agreement and Plan of Merger and Reorganization, dated as of March 24, 2024, by and among the Issuer, AnHeart Therapeutics Ltd. (\"AnHeart\"), Artemis Merger Sub I, Ltd., a wholly owned subsidiary of the Issuer (\"Merger Sub I\"), and Artemis Merger Sub II, Ltd., a wholly owned subsidiary of the Issuer (\"Merger Sub II\"), whereby Merger Sub I merged with and into AnHeart, with AnHeart surviving such merger as a direct, wholly owned subsidiary of the Issuer (the \"First Merger\"). Immediately following the First Merger, AnHeart, as the surviving company of the First Merger, merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Received pursuant to the Agreement and Plan of Merger and Reorganization, dated as of March 24, 2024, by and among the Issuer, AnHeart Therapeutics Ltd. (\"AnHeart\"), Artemis Merger Sub I, Ltd., a wholly owned subsidiary of the Issuer (\"Merger Sub I\"), and Artemis Merger Sub II, Ltd., a wholly owned subsidiary of the Issuer (\"Merger Sub II\"), whereby Merger Sub I merged with and into AnHeart, with AnHeart surviving such merger as a direct, wholly owned subsidiary of the Issuer (the \"First Merger\"). Immediately following the First Merger, AnHeart, as the surviving company of the First Merger, merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Upon satisfaction of the Convertibility Condition, the Warrants became exercisable for Class A common stock at any time at the option of the holder."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are owned directly by Decheng Capital Global Healthcare Fund (Master), LP (\"Healthcare\"). The Reporting Person is the indirect managing member and ultimate beneficial owner of Decheng Capital Global Healthcare GP, LLC, the general partner of Healthcare. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein."}],"balance_after":175346,"derivative":{"exercise_price":11.5,"expiration_date":"2029-04-09","underlying":"Class A Common Stock","underlying_shares":175346},"source":{"system":"sec-edgar","filing":"0001415889-24-022899","document":"form4-09052024_040901.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1811063/000141588924022899/form4-09052024_040901.xml","form_type":"4"}},{"id":1414054,"issuer":{"id":4384,"kind":"organization","name":"Nuvation Bio Inc."},"owners":[{"id":44249,"kind":"person","name":"Cui Xiangmin","position":1,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (Right to Buy)","published_at":"2024-09-05T20:15:06.000Z","date":"2024-09-03","kind":"grant","planned":false,"acquired":true,"shares":32877,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"date","element":"transactionDate","label":"F6","text":"The Series A Preferred Stock and Warrants were originally acquired on April 9, 2024. Upon issuance, the Series A Preferred Stock was not convertible into, and the Warrants were not exercisable for, Class A common stock until the Issuer's stockholders approved the issuance of the Class A common stock issuable upon conversion of the Series A Preferred Stock and exercise of Warrants (the \"Convertibility Condition\"). Because of the Convertibility Condition, the Series A Preferred Stock and the Warrants were not considered derivative securities and were, therefore, not reportable under Section 16 of the Securities Exchange Act, until such condition was satisfied. The Convertibility Condition was satisfied on September 3, 2024."},{"field":"shares","element":"transactionShares","label":"F7","text":"Received pursuant to the Agreement and Plan of Merger and Reorganization, dated as of March 24, 2024, by and among the Issuer, AnHeart Therapeutics Ltd. (\"AnHeart\"), Artemis Merger Sub I, Ltd., a wholly owned subsidiary of the Issuer (\"Merger Sub I\"), and Artemis Merger Sub II, Ltd., a wholly owned subsidiary of the Issuer (\"Merger Sub II\"), whereby Merger Sub I merged with and into AnHeart, with AnHeart surviving such merger as a direct, wholly owned subsidiary of the Issuer (the \"First Merger\"). Immediately following the First Merger, AnHeart, as the surviving company of the First Merger, merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Received pursuant to the Agreement and Plan of Merger and Reorganization, dated as of March 24, 2024, by and among the Issuer, AnHeart Therapeutics Ltd. (\"AnHeart\"), Artemis Merger Sub I, Ltd., a wholly owned subsidiary of the Issuer (\"Merger Sub I\"), and Artemis Merger Sub II, Ltd., a wholly owned subsidiary of the Issuer (\"Merger Sub II\"), whereby Merger Sub I merged with and into AnHeart, with AnHeart surviving such merger as a direct, wholly owned subsidiary of the Issuer (the \"First Merger\"). Immediately following the First Merger, AnHeart, as the surviving company of the First Merger, merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Upon satisfaction of the Convertibility Condition, the Warrants became exercisable for Class A common stock at any time at the option of the holder."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are owned directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). The Reporting Person is the manager of Decheng Capital Management III (Cayman), LLC, the general partner of Fund III. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein."}],"balance_after":32877,"derivative":{"exercise_price":11.5,"expiration_date":"2029-04-09","underlying":"Class A Common Stock","underlying_shares":32877},"source":{"system":"sec-edgar","filing":"0001415889-24-022899","document":"form4-09052024_040901.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1811063/000141588924022899/form4-09052024_040901.xml","form_type":"4"}},{"id":1414053,"issuer":{"id":4384,"kind":"organization","name":"Nuvation Bio Inc."},"owners":[{"id":44249,"kind":"person","name":"Cui Xiangmin","position":1,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2024-09-05T20:15:06.000Z","date":"2024-09-03","kind":"grant","planned":false,"acquired":true,"shares":128792,"ownership":{"direct":false,"nature":"By Decheng Anbio Limited"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Upon satisfaction of the Convertibility Condition, each share of Series A Preferred Stock became automatically convertible into 100 shares of Class A common stock, for no additional consideration, effective as of 5:00 p.m. Eastern time on September 4, 2024."},{"field":"date","element":"transactionDate","label":"F6","text":"The Series A Preferred Stock and Warrants were originally acquired on April 9, 2024. Upon issuance, the Series A Preferred Stock was not convertible into, and the Warrants were not exercisable for, Class A common stock until the Issuer's stockholders approved the issuance of the Class A common stock issuable upon conversion of the Series A Preferred Stock and exercise of Warrants (the \"Convertibility Condition\"). Because of the Convertibility Condition, the Series A Preferred Stock and the Warrants were not considered derivative securities and were, therefore, not reportable under Section 16 of the Securities Exchange Act, until such condition was satisfied. The Convertibility Condition was satisfied on September 3, 2024."},{"field":"shares","element":"transactionShares","label":"F7","text":"Received pursuant to the Agreement and Plan of Merger and Reorganization, dated as of March 24, 2024, by and among the Issuer, AnHeart Therapeutics Ltd. (\"AnHeart\"), Artemis Merger Sub I, Ltd., a wholly owned subsidiary of the Issuer (\"Merger Sub I\"), and Artemis Merger Sub II, Ltd., a wholly owned subsidiary of the Issuer (\"Merger Sub II\"), whereby Merger Sub I merged with and into AnHeart, with AnHeart surviving such merger as a direct, wholly owned subsidiary of the Issuer (the \"First Merger\"). Immediately following the First Merger, AnHeart, as the surviving company of the First Merger, merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Received pursuant to the Agreement and Plan of Merger and Reorganization, dated as of March 24, 2024, by and among the Issuer, AnHeart Therapeutics Ltd. (\"AnHeart\"), Artemis Merger Sub I, Ltd., a wholly owned subsidiary of the Issuer (\"Merger Sub I\"), and Artemis Merger Sub II, Ltd., a wholly owned subsidiary of the Issuer (\"Merger Sub II\"), whereby Merger Sub I merged with and into AnHeart, with AnHeart surviving such merger as a direct, wholly owned subsidiary of the Issuer (the \"First Merger\"). Immediately following the First Merger, AnHeart, as the surviving company of the First Merger, merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Upon satisfaction of the Convertibility Condition, each share of Series A Preferred Stock became automatically convertible into 100 shares of Class A common stock, for no additional consideration, effective as of 5:00 p.m. Eastern time on September 4, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Upon satisfaction of the Convertibility Condition, each share of Series A Preferred Stock became automatically convertible into 100 shares of Class A common stock, for no additional consideration, effective as of 5:00 p.m. Eastern time on September 4, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are owned directly by Decheng Anbio Limited (\"SPV\"). The Reporting Person is a director of SPV. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein."}],"balance_after":128792,"derivative":{"underlying":"Class A Common Stock","underlying_shares":12879200},"source":{"system":"sec-edgar","filing":"0001415889-24-022899","document":"form4-09052024_040901.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1811063/000141588924022899/form4-09052024_040901.xml","form_type":"4"}},{"id":1414052,"issuer":{"id":4384,"kind":"organization","name":"Nuvation Bio Inc."},"owners":[{"id":44249,"kind":"person","name":"Cui Xiangmin","position":1,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2024-09-05T20:15:06.000Z","date":"2024-09-03","kind":"grant","planned":false,"acquired":true,"shares":51579,"ownership":{"direct":false,"nature":"By Decheng Capital Global Healthcare Fund (Master), LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Upon satisfaction of the Convertibility Condition, each share of Series A Preferred Stock became automatically convertible into 100 shares of Class A common stock, for no additional consideration, effective as of 5:00 p.m. Eastern time on September 4, 2024."},{"field":"date","element":"transactionDate","label":"F6","text":"The Series A Preferred Stock and Warrants were originally acquired on April 9, 2024. Upon issuance, the Series A Preferred Stock was not convertible into, and the Warrants were not exercisable for, Class A common stock until the Issuer's stockholders approved the issuance of the Class A common stock issuable upon conversion of the Series A Preferred Stock and exercise of Warrants (the \"Convertibility Condition\"). Because of the Convertibility Condition, the Series A Preferred Stock and the Warrants were not considered derivative securities and were, therefore, not reportable under Section 16 of the Securities Exchange Act, until such condition was satisfied. The Convertibility Condition was satisfied on September 3, 2024."},{"field":"shares","element":"transactionShares","label":"F7","text":"Received pursuant to the Agreement and Plan of Merger and Reorganization, dated as of March 24, 2024, by and among the Issuer, AnHeart Therapeutics Ltd. (\"AnHeart\"), Artemis Merger Sub I, Ltd., a wholly owned subsidiary of the Issuer (\"Merger Sub I\"), and Artemis Merger Sub II, Ltd., a wholly owned subsidiary of the Issuer (\"Merger Sub II\"), whereby Merger Sub I merged with and into AnHeart, with AnHeart surviving such merger as a direct, wholly owned subsidiary of the Issuer (the \"First Merger\"). Immediately following the First Merger, AnHeart, as the surviving company of the First Merger, merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Received pursuant to the Agreement and Plan of Merger and Reorganization, dated as of March 24, 2024, by and among the Issuer, AnHeart Therapeutics Ltd. (\"AnHeart\"), Artemis Merger Sub I, Ltd., a wholly owned subsidiary of the Issuer (\"Merger Sub I\"), and Artemis Merger Sub II, Ltd., a wholly owned subsidiary of the Issuer (\"Merger Sub II\"), whereby Merger Sub I merged with and into AnHeart, with AnHeart surviving such merger as a direct, wholly owned subsidiary of the Issuer (the \"First Merger\"). Immediately following the First Merger, AnHeart, as the surviving company of the First Merger, merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Upon satisfaction of the Convertibility Condition, each share of Series A Preferred Stock became automatically convertible into 100 shares of Class A common stock, for no additional consideration, effective as of 5:00 p.m. Eastern time on September 4, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Upon satisfaction of the Convertibility Condition, each share of Series A Preferred Stock became automatically convertible into 100 shares of Class A common stock, for no additional consideration, effective as of 5:00 p.m. Eastern time on September 4, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are owned directly by Decheng Capital Global Healthcare Fund (Master), LP (\"Healthcare\"). The Reporting Person is the indirect managing member and ultimate beneficial owner of Decheng Capital Global Healthcare GP, LLC, the general partner of Healthcare. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein."}],"balance_after":51579,"derivative":{"underlying":"Class A Common Stock","underlying_shares":5157900},"source":{"system":"sec-edgar","filing":"0001415889-24-022899","document":"form4-09052024_040901.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1811063/000141588924022899/form4-09052024_040901.xml","form_type":"4"}},{"id":1414051,"issuer":{"id":4384,"kind":"organization","name":"Nuvation Bio Inc."},"owners":[{"id":44249,"kind":"person","name":"Cui Xiangmin","position":1,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2024-09-05T20:15:06.000Z","date":"2024-09-03","kind":"grant","planned":false,"acquired":true,"shares":9671,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Upon satisfaction of the Convertibility Condition, each share of Series A Preferred Stock became automatically convertible into 100 shares of Class A common stock, for no additional consideration, effective as of 5:00 p.m. Eastern time on September 4, 2024."},{"field":"date","element":"transactionDate","label":"F6","text":"The Series A Preferred Stock and Warrants were originally acquired on April 9, 2024. Upon issuance, the Series A Preferred Stock was not convertible into, and the Warrants were not exercisable for, Class A common stock until the Issuer's stockholders approved the issuance of the Class A common stock issuable upon conversion of the Series A Preferred Stock and exercise of Warrants (the \"Convertibility Condition\"). Because of the Convertibility Condition, the Series A Preferred Stock and the Warrants were not considered derivative securities and were, therefore, not reportable under Section 16 of the Securities Exchange Act, until such condition was satisfied. The Convertibility Condition was satisfied on September 3, 2024."},{"field":"shares","element":"transactionShares","label":"F7","text":"Received pursuant to the Agreement and Plan of Merger and Reorganization, dated as of March 24, 2024, by and among the Issuer, AnHeart Therapeutics Ltd. (\"AnHeart\"), Artemis Merger Sub I, Ltd., a wholly owned subsidiary of the Issuer (\"Merger Sub I\"), and Artemis Merger Sub II, Ltd., a wholly owned subsidiary of the Issuer (\"Merger Sub II\"), whereby Merger Sub I merged with and into AnHeart, with AnHeart surviving such merger as a direct, wholly owned subsidiary of the Issuer (the \"First Merger\"). Immediately following the First Merger, AnHeart, as the surviving company of the First Merger, merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Received pursuant to the Agreement and Plan of Merger and Reorganization, dated as of March 24, 2024, by and among the Issuer, AnHeart Therapeutics Ltd. (\"AnHeart\"), Artemis Merger Sub I, Ltd., a wholly owned subsidiary of the Issuer (\"Merger Sub I\"), and Artemis Merger Sub II, Ltd., a wholly owned subsidiary of the Issuer (\"Merger Sub II\"), whereby Merger Sub I merged with and into AnHeart, with AnHeart surviving such merger as a direct, wholly owned subsidiary of the Issuer (the \"First Merger\"). Immediately following the First Merger, AnHeart, as the surviving company of the First Merger, merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Upon satisfaction of the Convertibility Condition, each share of Series A Preferred Stock became automatically convertible into 100 shares of Class A common stock, for no additional consideration, effective as of 5:00 p.m. Eastern time on September 4, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Upon satisfaction of the Convertibility Condition, each share of Series A Preferred Stock became automatically convertible into 100 shares of Class A common stock, for no additional consideration, effective as of 5:00 p.m. Eastern time on September 4, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are owned directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). The Reporting Person is the manager of Decheng Capital Management III (Cayman), LLC, the general partner of Fund III. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein."}],"balance_after":9671,"derivative":{"underlying":"Class A Common Stock","underlying_shares":967100},"source":{"system":"sec-edgar","filing":"0001415889-24-022899","document":"form4-09052024_040901.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1811063/000141588924022899/form4-09052024_040901.xml","form_type":"4"}},{"id":1414050,"issuer":{"id":4384,"kind":"organization","name":"Nuvation Bio Inc."},"owners":[{"id":44249,"kind":"person","name":"Cui Xiangmin","position":1,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-09-05T20:15:06.000Z","date":"2024-09-04","kind":"exercise","planned":false,"acquired":true,"shares":12879200,"ownership":{"direct":false,"nature":"By Decheng Anbio Limited"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In accordance with the Certificate of Designation of Preferences, Rights and Limitations of the Series A Non-Voting Convertible Preferred Stock (the \"Series A Preferred Stock\"), these shares of Series A Preferred Stock were automatically converted to Class A common stock based on the conversion ratio described in footnote 5, for no additional consideration, effective as of 5:00 p.m. Eastern time on September 4, 2024, the first business day following the satisfaction of the Convertibility Condition (as defined in footnote 6)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are owned directly by Decheng Anbio Limited (\"SPV\"). The Reporting Person is a director of SPV. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein."}],"balance_after":17062202,"source":{"system":"sec-edgar","filing":"0001415889-24-022899","document":"form4-09052024_040901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1811063/000141588924022899/form4-09052024_040901.xml","form_type":"4"}},{"id":1414049,"issuer":{"id":4384,"kind":"organization","name":"Nuvation Bio Inc."},"owners":[{"id":44249,"kind":"person","name":"Cui Xiangmin","position":1,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-09-05T20:15:06.000Z","date":"2024-09-04","kind":"exercise","planned":false,"acquired":true,"shares":5157900,"ownership":{"direct":false,"nature":"By Decheng Capital Global Healthcare Fund (Master), LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In accordance with the Certificate of Designation of Preferences, Rights and Limitations of the Series A Non-Voting Convertible Preferred Stock (the \"Series A Preferred Stock\"), these shares of Series A Preferred Stock were automatically converted to Class A common stock based on the conversion ratio described in footnote 5, for no additional consideration, effective as of 5:00 p.m. Eastern time on September 4, 2024, the first business day following the satisfaction of the Convertibility Condition (as defined in footnote 6)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are owned directly by Decheng Capital Global Healthcare Fund (Master), LP (\"Healthcare\"). The Reporting Person is the indirect managing member and ultimate beneficial owner of Decheng Capital Global Healthcare GP, LLC, the general partner of Healthcare. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein."}],"balance_after":7611031,"source":{"system":"sec-edgar","filing":"0001415889-24-022899","document":"form4-09052024_040901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1811063/000141588924022899/form4-09052024_040901.xml","form_type":"4"}},{"id":1414048,"issuer":{"id":4384,"kind":"organization","name":"Nuvation Bio Inc."},"owners":[{"id":44249,"kind":"person","name":"Cui Xiangmin","position":1,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-09-05T20:15:06.000Z","date":"2024-09-04","kind":"exercise","planned":false,"acquired":true,"shares":967100,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In accordance with the Certificate of Designation of Preferences, Rights and Limitations of the Series A Non-Voting Convertible Preferred Stock (the \"Series A Preferred Stock\"), these shares of Series A Preferred Stock were automatically converted to Class A common stock based on the conversion ratio described in footnote 5, for no additional consideration, effective as of 5:00 p.m. Eastern time on September 4, 2024, the first business day following the satisfaction of the Convertibility Condition (as defined in footnote 6)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are owned directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). The Reporting Person is the manager of Decheng Capital Management III (Cayman), LLC, the general partner of Fund III. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein."}],"balance_after":1281206,"source":{"system":"sec-edgar","filing":"0001415889-24-022899","document":"form4-09052024_040901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1811063/000141588924022899/form4-09052024_040901.xml","form_type":"4"}},{"id":1468781,"issuer":{"id":4384,"kind":"organization","name":"Nuvation Bio Inc."},"owners":[{"id":44249,"kind":"person","name":"Cui Xiangmin","position":1,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-06-26T20:31:59.000Z","date":"2024-06-25","kind":"purchase","planned":false,"acquired":true,"shares":277895,"price":2.97,"value":825348.15,"ownership":{"direct":false,"nature":"By Decheng Capital Global Healthcare Fund (Master), LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.92 to $3.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are owned directly by Decheng Capital Global Healthcare Fund (Master), LP (\"Healthcare\"). The Reporting Person is the indirect managing member and ultimate beneficial owner of Decheng Capital Global Healthcare GP, LLC, the general partner of Healthcare. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein."}],"balance_after":2453131,"source":{"system":"sec-edgar","filing":"0001415889-24-018231","document":"form4-06262024_080655.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1811063/000141588924018231/form4-06262024_080655.xml","form_type":"4"}},{"id":1469588,"issuer":{"id":4384,"kind":"organization","name":"Nuvation Bio Inc."},"owners":[{"id":44249,"kind":"person","name":"Cui Xiangmin","position":1,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-06-25T21:45:38.000Z","date":"2024-06-24","kind":"purchase","planned":false,"acquired":true,"shares":336874,"price":2.98,"value":1003884.52,"ownership":{"direct":false,"nature":"By Decheng Capital Global Healthcare Fund (Master), LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.93 to $3.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are owned directly by Decheng Capital Global Healthcare Fund (Master), LP (\"Healthcare\"). The Reporting Person is the indirect managing member and ultimate beneficial owner of Decheng Capital Global Healthcare GP, LLC, the general partner of Healthcare. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein."}],"balance_after":2175236,"source":{"system":"sec-edgar","filing":"0001415889-24-018162","document":"form4-06252024_090633.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1811063/000141588924018162/form4-06252024_090633.xml","form_type":"4"}},{"id":1469587,"issuer":{"id":4384,"kind":"organization","name":"Nuvation Bio Inc."},"owners":[{"id":44249,"kind":"person","name":"Cui Xiangmin","position":1,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-06-25T21:45:38.000Z","date":"2024-06-21","kind":"purchase","planned":false,"acquired":true,"shares":75411,"price":3,"value":226233.0,"ownership":{"direct":false,"nature":"By Decheng Capital Global Healthcare Fund (Master), LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.99 to $3.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are owned directly by Decheng Capital Global Healthcare Fund (Master), LP (\"Healthcare\"). The Reporting Person is the indirect managing member and ultimate beneficial owner of Decheng Capital Global Healthcare GP, LLC, the general partner of Healthcare. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein."}],"balance_after":1838362,"source":{"system":"sec-edgar","filing":"0001415889-24-018162","document":"form4-06252024_090633.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1811063/000141588924018162/form4-06252024_090633.xml","form_type":"4"}},{"id":1469586,"issuer":{"id":4384,"kind":"organization","name":"Nuvation Bio Inc."},"owners":[{"id":44249,"kind":"person","name":"Cui Xiangmin","position":1,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-06-25T21:45:38.000Z","date":"2024-06-20","kind":"purchase","planned":false,"acquired":true,"shares":87715,"price":2.99,"value":262267.85,"ownership":{"direct":false,"nature":"By Decheng Capital Global Healthcare Fund (Master), LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.90 to $3.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are owned directly by Decheng Capital Global Healthcare Fund (Master), LP (\"Healthcare\"). The Reporting Person is the indirect managing member and ultimate beneficial owner of Decheng Capital Global Healthcare GP, LLC, the general partner of Healthcare. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein."}],"balance_after":1762951,"source":{"system":"sec-edgar","filing":"0001415889-24-018162","document":"form4-06252024_090633.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1811063/000141588924018162/form4-06252024_090633.xml","form_type":"4"}},{"id":1508933,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":44249,"kind":"person","name":"Cui Xiangmin","position":1,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":2,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":3,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-21T00:08:26.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"(Continued from Footnote 7)  Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"1/12th of the shares subject to the option become vested and exercisable on February 2, 2024 and 1/12 of the shares subject to the option shall vest monthly thereafter."}],"balance_after":0,"derivative":{"exercise_price":19,"expiration_date":"2034-01-01","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001626199-24-000095","document":"wk-form4_1716250094.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000162619924000095/wk-form4_1716250094.xml","form_type":"4"}},{"id":1508932,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":44249,"kind":"person","name":"Cui Xiangmin","position":1,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":2,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":3,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-21T00:08:26.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"(Continued from Footnote 7)  Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":7.43,"expiration_date":"2033-01-02","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001626199-24-000095","document":"wk-form4_1716250094.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000162619924000095/wk-form4_1716250094.xml","form_type":"4"}},{"id":1508931,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":44249,"kind":"person","name":"Cui Xiangmin","position":1,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":2,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":3,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-21T00:08:26.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"(Continued from Footnote 7)  Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":13.89,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001626199-24-000095","document":"wk-form4_1716250094.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000162619924000095/wk-form4_1716250094.xml","form_type":"4"}},{"id":1508930,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":44249,"kind":"person","name":"Cui Xiangmin","position":1,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":2,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":3,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-21T00:08:26.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7650,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"(Continued from Footnote 7)  Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":13.45,"expiration_date":"2031-01-03","underlying":"Common Stock","underlying_shares":7650},"source":{"system":"sec-edgar","filing":"0001626199-24-000095","document":"wk-form4_1716250094.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000162619924000095/wk-form4_1716250094.xml","form_type":"4"}},{"id":1508929,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":44249,"kind":"person","name":"Cui Xiangmin","position":1,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":2,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":3,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-21T00:08:26.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7650,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"(Continued from Footnote 7)  Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":3.6233,"expiration_date":"2030-01-01","underlying":"Common Stock","underlying_shares":7650},"source":{"system":"sec-edgar","filing":"0001626199-24-000095","document":"wk-form4_1716250094.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000162619924000095/wk-form4_1716250094.xml","form_type":"4"}},{"id":1508928,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":44249,"kind":"person","name":"Cui Xiangmin","position":1,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":2,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":3,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-21T00:08:26.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7650,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"(Continued from Footnote 7)  Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":5.7008,"expiration_date":"2029-01-17","underlying":"Common Stock","underlying_shares":7650},"source":{"system":"sec-edgar","filing":"0001626199-24-000095","document":"wk-form4_1716250094.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000162619924000095/wk-form4_1716250094.xml","form_type":"4"}},{"id":1508927,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":44249,"kind":"person","name":"Cui Xiangmin","position":1,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":2,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":3,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-05-21T00:08:26.000Z","date":"2024-05-18","kind":"other","planned":false,"acquired":false,"shares":1735544,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are owned directly by Decheng Capital Global Healthcare Fund (Master), LP (\"Healthcare\"). Xiangmin Cui is the indirect managing member and ultimate beneficial owner of Decheng Capital Global Healthcare GP, LLC, the general partner of Healthcare.  Dr. Cui disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001626199-24-000095","document":"wk-form4_1716250094.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000162619924000095/wk-form4_1716250094.xml","form_type":"4"}},{"id":1508926,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":44249,"kind":"person","name":"Cui Xiangmin","position":1,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74129,"kind":"organization","name":"Decheng Capital China Life Sciences USD Fund III, L.P.","position":2,"cik":"0001736814","reported_name":"Decheng Capital China Life Sciences USD Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74130,"kind":"organization","name":"Decheng Capital Management III (Cayman), LLC","position":3,"cik":"0001747821","reported_name":"Decheng Capital Management III (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":4,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":5,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-05-21T00:08:26.000Z","date":"2024-05-18","kind":"other","planned":false,"acquired":false,"shares":6582380,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are owned directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). Xiangmin Cui is the manager of Decheng Capital Management III (Cayman), LLC, the general partner of Fund III. Dr. Cui disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001626199-24-000095","document":"wk-form4_1716250094.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000162619924000095/wk-form4_1716250094.xml","form_type":"4"}},{"id":1543178,"issuer":{"id":4384,"kind":"organization","name":"Nuvation Bio Inc."},"owners":[{"id":44249,"kind":"person","name":"Cui Xiangmin","position":1,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-04-12T01:01:01.000Z","date":"2024-04-09","kind":"grant","planned":false,"acquired":true,"shares":4183002,"ownership":{"direct":false,"nature":"By Decheng Anbio Limited"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Received pursuant to the Agreement and Plan of Merger and Reorganization, dated as of March 24, 2024, by and among Nuvation Bio Inc. (the \"Issuer\"), AnHeart Therapeutics Ltd. (\"AnHeart\"), Artemis Merger Sub I, Ltd., a wholly owned subsidiary of the Issuer (\"Merger Sub I\"), and Artemis Merger Sub II, Ltd., a wholly owned subsidiary of the Issuer (\"Merger Sub II\"), whereby Merger Sub I merged with and into AnHeart, with AnHeart surviving such merger as a direct, wholly owned subsidiary of the Issuer (the \"First Merger\"). Immediately following the First Merger, AnHeart, as the surviving company of the First Merger, merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of the Issuer (the \"Second Merger\" and,\ncollectively with the First Merger, as appropriate, the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Received in exchange for 7,200,000 Series A Preferred shares, 685,714 Series A+ Preferred shares and 487,231 Series B Preferred shares of AnHeart in connection with the Merger (as described in footnote 1) on April 9, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are owned directly by Decheng Anbio Limited (\"SPV\"). The Reporting Person is a director of SPV. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein."}],"balance_after":4183002,"source":{"system":"sec-edgar","filing":"0001415889-24-010738","document":"form4-04122024_010452.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1811063/000141588924010738/form4-04122024_010452.xml","form_type":"4"}},{"id":1543177,"issuer":{"id":4384,"kind":"organization","name":"Nuvation Bio Inc."},"owners":[{"id":44249,"kind":"person","name":"Cui Xiangmin","position":1,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-04-12T01:01:01.000Z","date":"2024-04-09","kind":"grant","planned":false,"acquired":true,"shares":1675236,"ownership":{"direct":false,"nature":"By Decheng Capital Global Healthcare Fund (Master), LP"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Received pursuant to the Agreement and Plan of Merger and Reorganization, dated as of March 24, 2024, by and among Nuvation Bio Inc. (the \"Issuer\"), AnHeart Therapeutics Ltd. (\"AnHeart\"), Artemis Merger Sub I, Ltd., a wholly owned subsidiary of the Issuer (\"Merger Sub I\"), and Artemis Merger Sub II, Ltd., a wholly owned subsidiary of the Issuer (\"Merger Sub II\"), whereby Merger Sub I merged with and into AnHeart, with AnHeart surviving such merger as a direct, wholly owned subsidiary of the Issuer (the \"First Merger\"). Immediately following the First Merger, AnHeart, as the surviving company of the First Merger, merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of the Issuer (the \"Second Merger\" and,\ncollectively with the First Merger, as appropriate, the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Received in exchange for 2,388,578 Series B Preferred shares of AnHeart in connection with the Merger (as described in footnote 1) on April 9, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are owned directly by Decheng Capital Global Healthcare Fund (Master), LP (\"Healthcare\"). The Reporting Person is the indirect managing member and ultimate beneficial owner of Decheng Capital Global Healthcare GP, LLC, the general partner of Healthcare. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein."}],"balance_after":1675236,"source":{"system":"sec-edgar","filing":"0001415889-24-010738","document":"form4-04122024_010452.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1811063/000141588924010738/form4-04122024_010452.xml","form_type":"4"}},{"id":1543176,"issuer":{"id":4384,"kind":"organization","name":"Nuvation Bio Inc."},"owners":[{"id":44249,"kind":"person","name":"Cui Xiangmin","position":1,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-04-12T01:01:01.000Z","date":"2024-04-09","kind":"grant","planned":false,"acquired":true,"shares":314106,"ownership":{"direct":false,"nature":"By Decheng Capital China Life Sciences USD Fund III, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Received pursuant to the Agreement and Plan of Merger and Reorganization, dated as of March 24, 2024, by and among Nuvation Bio Inc. (the \"Issuer\"), AnHeart Therapeutics Ltd. (\"AnHeart\"), Artemis Merger Sub I, Ltd., a wholly owned subsidiary of the Issuer (\"Merger Sub I\"), and Artemis Merger Sub II, Ltd., a wholly owned subsidiary of the Issuer (\"Merger Sub II\"), whereby Merger Sub I merged with and into AnHeart, with AnHeart surviving such merger as a direct, wholly owned subsidiary of the Issuer (the \"First Merger\"). Immediately following the First Merger, AnHeart, as the surviving company of the First Merger, merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of the Issuer (the \"Second Merger\" and,\ncollectively with the First Merger, as appropriate, the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in exchange for 447,858 Series B Preferred shares of AnHeart in connection with the Merger (as described in footnote 1) on April 9, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are owned directly by Decheng Capital China Life Sciences USD Fund III, L.P. (\"Fund III\"). The Reporting Person is the manager of Decheng Capital Management III (Cayman), LLC, the general partner of Fund III. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein."}],"balance_after":314106,"source":{"system":"sec-edgar","filing":"0001415889-24-010738","document":"form4-04122024_010452.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1811063/000141588924010738/form4-04122024_010452.xml","form_type":"4"}},{"id":1544513,"issuer":{"id":3735,"kind":"organization","name":"CG Oncology, Inc.","symbol":"CGON"},"owners":[{"id":83056,"kind":"organization","name":"Decheng Capital Global Life Sciences Fund IV, L.P.","position":1,"cik":"0001834150","reported_name":"Decheng Capital Global Life Sciences Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":83057,"kind":"organization","name":"Decheng Capital Management IV (Cayman), LLC","position":2,"cik":"0001843384","reported_name":"Decheng Capital Management IV (Cayman), LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74133,"kind":"organization","name":"Decheng Capital Global Healthcare Fund (Master), LP","position":3,"cik":"0001949026","reported_name":"Decheng Capital Global Healthcare Fund (Master), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74134,"kind":"organization","name":"Decheng Capital Global Healthcare GP, LLC","position":4,"cik":"0001949027","reported_name":"Decheng Capital Global Healthcare GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44249,"kind":"person","name":"Cui Xiangmin","position":5,"cik":"0001487815","reported_name":"Cui Xiangmin","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-09T23:08:23.000Z","date":"2024-01-29","kind":"purchase","planned":false,"acquired":true,"shares":400000,"price":19,"value":7600000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"These securities are held directly by Decheng Capital Global Life Sciences Fund IV, L.P. (\"Fund IV\"). Decheng Capital Management IV (Cayman), LLC (\"GP IV\") is the general partner of Fund IV. Xiangmin Cui is the manager of GP IV. Each of Fund IV, GP IV and Dr. Cui may be deemed to beneficially own the securities held by Fund IV. Each of GP IV and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein."}],"balance_after":4958810,"source":{"system":"sec-edgar","filing":"0001415889-24-010609","document":"form4a-04092024_110416.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1487815/000141588924010609/form4a-04092024_110416.xml","form_type":"4/A","original_submission_date":"2024-01-31"}}],"next_cursor":"2024-04-09T23:08:23.000000Z,1544513"}